KOD

Kodiak Sciences Inc.

Phase 3 Confirmed

Zenkuda (tarcocimab tedromer)

diabetic retinopathy

Resolved

103days ago

Phase 3 readout · Mar 26, 2026

What's at stake Phase 3 trial results for Zenkuda (tarcocimab tedromer) in diabetic retinopathy are due Mar 26, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 13h ago

“Zenkuda now has a multi-indication Biologics License Application (BLA)-ready profile, and Kodiak intends to accelerate the BLA submission timeline.”

Add to calendar Post on X Reddit

Provenance